Targeting the Underlying Causes of Diabetes



There is a cure for autoimmune diabetes

What We Do

We develop therapies for the treatment of diabetes

Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development.

Two disease-modifying therapies are being developed, the antigen-specific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapy Remygen®.

Diamyd® and Remygen® target the underlying causes of diabetes, the dysfunction and loss of the insulin producing beta cells in the pancreas. Diamyd® and Remygen® are currently being evaluated in clinical trials.

Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.



Diamyd® and Remygen® are drugs in clinical development phase targeting the underlying causes of diabetes, the dysfunction and loss of the pancreatic beta cells.


The results have been received with great interest during partner discussions and show the potential of intralymphatic injections of Diamyd®.

Ulf Hannelius
President and CEO, Diamyd Medical AB



A small number of employees constitute Diamyd Medical's core which collaborates with a global network of clinics, researchers and production units. Regulatory expertise and analysis- and laboratory services are contracted as needed during the project phases. The model is based on long-term collaborations, internal core competence and cost efficiency.